FDA Brief

Warning letters Food

FDA warning letter to

Honey Feast, Inc.

LowIssued Mar 17, 2022Posted Apr 5, 2022Office of Human and Animal Food Operations East Division IV

Honey Feast, Inc. sold honey products online with disease-treatment claims, making them unapproved new drugs and misbranded.

What happened

FDA reviewed honeyfeast.com in February through March 2022 and found blog posts claiming Raw Honeycomb; Tupelo Honey Raw; and Superfood Honey with Royal Jelly, Bee Pollen, Propolis could treat or prevent diseases such as ulcers, wounds, coughs, heart disease, and cancer. FDA said these claims make the products drugs, but they are not generally recognized as safe and effective for those uses and lack FDA approval. FDA also said the products lack adequate directions for use and are therefore misbranded.

What FDA found

  1. Website claims show the products are intended to cure, mitigate, treat, or prevent disease, so they are drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for the claimed uses.

    section 201(p) of the Act [21 U.S.C. 321(p)]
  3. The new drugs were introduced or delivered for introduction into interstate commerce without FDA approval.

    sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]
  4. The products fail to bear adequate directions for use for their intended disease uses.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  5. Introducing misbranded drugs into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks Honey Feast to notify it in writing within 15 working days of the steps taken to address the violations, including an explanation of how each step prevents recurrence and copies of related documentation. If corrections cannot be completed in that time, the company must state the reason for the delay and when it will finish.

Who should pay attention

  • honey and food brands making health claims
  • e-commerce food and supplement marketers
  • companies with blog content claiming disease treatment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk